Introduction
Adaptive resistance refers to reversible refractoriness to the bactericidal action of an antibiotic following first exposure. The phenomenon has been well documented in Pseudomonas aeruginosa following exposure to an aminoglycoside (Gilleland, 1988; Gilleland et al., 1989; Daikos el al., 1990; Daikos, Lolans & Jackson, 1991; Barclay, Begg & Chambers, 1992) but also occurs in other Gram-negative bacteria (Daikos et al., 1990; Gould et al., 1991) and has been shown with ciprofloxacin (Gould et al., 1991) . For aminoglycosides, the mechanism of adaptive resistance appears to relate to reversible down-regulation of drug uptake into the bacteria, especially during the period of accelerated energy-dependent drug transport (Daikos et al., 1990) . The period of adaptive resistance to an aminoglycoside is dependent on the model in which it is investigated. In mice, which have short drug half-lives, adaptive resistance lasted for 8 h after single doses of netilmicin (Daikos et al., 1991) . In a dynamic in-vitro model of infection which simulates human pharmacokinetics, adaptive resistance was maximal for 10-16 h following a single dose of gentamicin, with return of susceptibility to baseline at approximately 40 h (Barclay et al., 1992) . Multiple dosing may lead to longer periods of adaptive resistance (Karlowsky et al., 1994) . Adaptive resistance has not, to our knowledge, been described in infections in humans.
Patients with cystic fibrosis (CF) frequently develop lung colonization with P. aeruginosa. Once infection is established it is very difficult to eradicate. Aminoglycosides remain important in the treatment of P. aeruginosa lung infection despite the development of newer agents with less toxicity (Lindsay & Bosso, 1993) . However, aminoglycoside bactericidal activity is reduced in sputum due to a number of factors including bacterial biofilms (Gilbert, Collier & Brown, 1990) , the slow growth phase of established infecting bacteria (Gilbert et al., 1990) , macromolecular binding of aminoglycosides (Ramphal et al., 1988; Bataillon et al., 1992; Levy et al., 1983) and the ionic milieu of sputum (Levy et al., 1983) . The induction of adaptive resistance in P. aeruginosa by aminoglycoside treatment may be another important factor causing reduced antibacterial activity.
The aims of this study were, firstly, to determine whether adaptive resistance was induced by tobramycin in P. aeruginosa in the sputum of patients with CF and, if so, to determine the time-course of the adaptive resistance following a single dose of tobramycin.
Methods

Patients and materials
Cystic fibrosis patients were studied if: (1) they could produce at least 1 mg of sputum per h, which was suitable for study; (2) they had in their sputum at least 10 7 cfu/mg of P. aeruginosa and; (3) the P. aeruginosa was sensitive to tobramycin by standard laboratory susceptibility testing. The study was approved by the Southern Regional Heatlh Authority Ethics Committee (Canterbury, New Zealand) and informed consent was obtained from patients or their parents. Tobramycin stock solution for in-vitro use was prepared from laboratory standard powder (Sigma Chemicals Co., St Louis, U.S.A.) and was stored at -70°C until the day of use. Bacterial counts were made by plating serial 10-fold dilutions of samples onto blood agar plates. An antibiotic carryover effect was excluded by diluting samples at least 200-fold before plating. Oxidase reaction, culture in oxidative/fermentative media (OF basal medium, Gibco BRL, Life Technologies, MD, USA) with 1% glucose, culture on cetrimide/nalidixic acid agar, and growth at 42°C on blood agar, were used to confirm that the colonies that were counted were P. aeruginosa. A fluorescence polarisation immunoassay (Abbott TDx, North Chicago, IL, USA) was used to measure sputum tobramycin concentrations. Nebuliser air compressors used were; a System 22, Model CR60 (Medic-Aid Ltd., Pagham, Sussex, UK-flow rate 6.5 L/min) and an A. R. Harris Model 6026 (Thomas Industries Inc, Sheboygan, WI, USA-flow rate 7.2 L/min). The nebuliser units used were a Ventstream (Medic-Aid Ltd., Sussex, UK) and Iso-Neb (Hudson Respiratory Care Inc., Temecula, CA, USA).
Two methods of processing sputum samples were used. Method 1 was used to determine the presence and time-course of adaptive resistance which was induced by a single dose of inhaled tobramycin.
Method 1
Patients did not have antibiotic therapy for at least one week before the study. Eighty mg of tobramycin was administered by nebuliser. Samples of sputum (1-3 mg) were collected just before, and at 1, 4, 8, 12, 24 , and 48 h after, the dose of tobramycin. Each sample was diluted 1:2 with sterile Ringer's solution and homogenized in a sterile plastic specimen container by shaking with small glass beads in an orbital shaker (Gyrotory shaker-model G2, New Brunswick Scientific Co., Edison, NJ, USA) at 500 rpm for 10 min. The homogenised sample was diluted 1:10 in pre-warmed cation-supplemented Mueller-Hinton broth (MHB) (calcium content 20-25 mg/L, magnesium 10-12.5 mg/L). Duplicate aliquots were exposed to tobramycin 100 mg/L for 90 min at 37°C and bacterial counts made before and after exposure to determine bactericidal activity at each time point. Adaptive resistance was observed if bactericidal activity was reduced following the dose of tobramycin, and later returned to the baseline pre-dose value.
To determine whether observed reversible resistance was caused by either the selection of constitutively-resistant bacterial sub-populations or adaptive resistance, randomly selected P. aeruginosa colonies on agar plates from times before, during and after the period of observed resistance were stored for MIC measurement and for typing by pulsed field gel electrophoresis (Grothues & Tummler, 1991) .
Method 2
This method determined only the presence of adaptive resistance. It was used in patients in whom baseline bacterial susceptibilities could not be obtained because they were unable to stop antibiotic therapy.
Samples of sputum from patients on long-term inhaled aminoglycoside, 80 mg administered twice-daily were collected immediately before, and 4 h after, 80 mg of tobramycin administered by nebuliser. As in method 1, samples were homogenized and diluted in MHB, and bacterial counts were made before and after a 90 min exposure to tobramycin 100 mg/L to determine bactericidal activity at each time point. In addition, to obtain a suitable baseline for bacterial susceptibility, a pre-dose sample of homogenised sputum was diluted 1:10,000 in MHB to remove antibiotic, to allow adaptive resistance to resolve, and was incubated at 37°C for 24 h to obtain a culture in the static phase of growth. Another sample of homogenised sputum was sterilised by exposure to ethylene oxide for 10 h. At 24 h, 1 mL of sterilised sputum was added to 0.5 mL of the culture in the static phase of growth to match the bacterial count, and ionic and other conditions in a sample obtained directly from a patient. The culture was then diluted 1:10 in prewarmed MHB and bacterial susceptibility was retested by exposing duplicate samples to tobramycin 100 mg/L for 90 min at 37°C. An increase in susceptibility at this time was taken to indicate the earlier presence of adaptive resistance.
To assess whether ethylene oxide treatment affected the test of bacterial susceptibility, both methods were compared in the patients who were not on regular tobramycin treatment. Baseline bacterial susceptibility before tobramycin treatment, using method 1, was compared with bacterial susceptibility after analysis of the same sample of sputum by method 2. Pretreatment of sputum with ethylene oxide did not significantly alter the susceptibility of the bacteria. This experiment also confirmed that bacterial susceptibility was not altered by culture in MHB for 24 h.
Statistical analysis
Method I. Sputum bacterial counts at each time point were averaged for graphical representation. The half-life of elimination of tobramycin in the sputum for each patient was calculated using a pharmacokinetics computer program, TopFit (version 2.0, 1993, Gustav Fischer Verlag, Stuttgart, Germany). To determine whether any observed resistance was significant, analysis of variance with repeated measures was used to compare the results over time for bactericidal effect after exposure to tobramycin 100 mg/L for 90 min in vitro. If a statistically significant difference between results was shown then least significant difference analysis was performed to compare predose results with the results obtained at times after the dose of tobramycin by nebuliser.
Method 2. Analysis of variance with repeated measures was used to compare the results for bacterial susceptibility (assessed by 90 min exposure to tobramycin in vitro) before and after a dose of inhaled tobramycin and following culture of the bacteria in the absence of tobramycin for 24 h. If statistically significant differences were shown then paired comparisons among the three sets of mean results obtained at these times were performed using the least significant difference test.
Results
Three patients were studied with method 1 (two females aged 26 and 27 years, one male aged 22 years) and four patients were studied with method 2 (females aged 10, 13, 27 and 33 years). All patients had sputum colonisation with P. aeruginosa for at least 2 years. Three patients had more than one colonial morphotype of P. aeruginosa in their sputum. However, in each case there was one clearly dominant morphotype and only this was counted. Figure 1 shows the combined results of sputum bacterial counts and sputum tobramycin concentrations in the three patients assessed by method 1. No bactericidal effect was observed in vivo following the single dose of inhaled tobramycin. The peak tobramycin concentration in the sputum, measured in samples taken 5 min after the dose, ranged from 90 to 240 mg/L. The half-life of elimination of tobramycin from the sputum ranged from 1.9 to 2.1 h. Figure 2 shows bacterial killing results for each patient after P. aeruginosa in sputum samples was exposed to tobramycin 100 mg/L in vitro for 90 min. Bacterial resistance was observed at 1-4 h and remained present for at least 24 h. Susceptibility returned to baseline at a time between 24 and 48 h. Statistical analysis of the mean bacterial killing results at each time point confirmed that observed susceptibility between 1 and 24 h was significantly different from the baseline susceptibility (/> < 0.05). Figure 3 shows the results from the four patients assessed by method 2. In each case,
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Pre-dose 4 h post-dose 24 h after antibiotic removed Figure 3 . Mean bacterial killing results (and range), indicating bacterial susceptibility, from four patients on twice-daily tobramycin by nebuhser, when P. aeruginosa in homogenised sputum samples was exposed to tobramycin in vitro for 90 min Bacterial killing was assessed in samples taken before and 4 h after 80 mg of tobramycin was administered by nebuliser, and in a culture of the same bacteria after incubation for 24 h in the absence of tobramycin.
bacteria were resistant to a second exposure to tobramycin in vitro before, and 4 h after, a dose of inhaled tobramycin. The previous dose of inhaled tobramycin had been administered 8-13 h earlier. After culture in the absence of tobramycin for 24 h, bacteria were significantly more susceptible on exposure to tobramycin lOOmg/L (P < 0.05), consistent with the resolution of adaptive resistance.
MICs of tobramycin for the P. aeruginosa strains obtained from patients at different times during the study ranged from 0.5 to 8 mg/L using the broth macrodilution method. The MIC did not change by more than one doubling dilution for colonies of individual strains taken at times before, during, and after the period of observed adaptive resistance. Macrorestriction fragment pattern analysis of the whole bacterial genome with Spel, by pulsed field gel electrophoresis, showed that the P. aeruginosa strains from each of the seven CF patients were unrelated. However, for each patient the P. aeruginosa strains remained unchanged throughout the course of the experiment. This supports the hypothesis that reduced susceptibility to tobramycin was from adaptive resistance and not from the selection of resistant colonies with later overgrowth by the susceptible parent strain.
Discussion
We have shown that adaptive resistance to the bactericidal action of tobramycin occurred in P. aeruginosa in the sputum of seven patients with CF soon after a dose by inhalation. In patients on long-term twice-daily inhaled aminoglycoside treatment, resistance was still marked at the end of a dose interval. Following a single dose of inhaled tobramycin in patients who were not on regular aminoglycoside treatment, the time course of adaptive resistance was similar to that shown when human pharmacokinetics were simulated in vitro (Barclay et al., 1992) . Features of the resistance which militate against it being due to selection of mutant strains include reversibility, the constant nature of the MICs for bacteria obtained before, during, and after the period of resistance, and, most importantly, strain conservation demonstrated by sensitive genomic fingerprinting techniques.
Adaptive resistance to aminoglycoside antibiotics has been shown in vitro and in mouse models of infection but has not previously been documented in humans. Patients with CF were chosen for study because they have chronic P. aeruginosa lung infection, which can be studied with non-invasive sampling. The time course of resistance can be studied because bacteria are not eradicated by a dose of aminoglycoside.
The peak sputum tobramycin concentrations measured in this study are consistent with results from other studies of inhaled aminoglycoside, after adjustment is made for the different doses used (Ilowite, Gorvoy & Smaldone, 1987) . Despite sputum tobramycin concentrations of 90-240 mg/L, no measurable bactericidal activity was observed in vivo after a single dose of tobramycin. Others have found that courses of inhaled tobramycin have, however, led to a transient reduction in P. aeruginosa density by a factor of 100, by 28 days (Ramsey et al., 1993) . Systemic absorption following inhaled aminoglycoside is dose-dependent but very low, with recorded peak serum concentrations ranging from unrecordable following standard doses (80 mg twice-daily), to 2.5 mg/L after doses of 600 mg of gentamicin (Gappa et al., 1988; Zach, 1988; Cooney et al., 1994,) . Toxicity has not been recorded after aminoglycoside dosing by inhalation (Hodson, Penketh & Batten, 1981; Schaad et al., 1987; Gappa et al., 1988; Ramsey et al., 1993) , an obvious advantage of this route of administration.
A high concentration of tobramycin (100 mg/L) was needed to produce adequate baseline bactericidal activity in the samples exposed to tobramycin in vitro, despite prior 1:20 dilution of the sputum in nutrient media. This is consistent with studies showing that the presence of sputum markedly reduces the bactericidal activity of aminoglycosides (Davis & Bruns, 1978; Levy et al., 1983; Mendelman et al., 1985) . This is due to a number of factors, notably the avid binding of aminoglycosides to macromolecules in the sputum, especially DNA and acid mucin glycopeptides (Bataillon et al., 1992) , which leaves little free drug to kill bacteria. At a total tobramycin concentration of 100 mg/L in whole standardised sputum, the free tobramycin concentration has been shown to be only 3.5-5.6 mg/L (Bataillon et al., 1992) . If a larger dose of inhaled tobramycin had been used in this study, leading to a higher associated free drug concentration in the sputum, greater adaptive resistance might have been observed because the phenomenon has been shown to be dose-dependent (Barclay et al., 1992) . In addition to drug-binding, the slow growth of bacteria associated with biofilms (Gilbert et al., 1990) , and other factors including low endobronchial pH and the ionic milieu of sputum (Levy et al., 1983) , have also been implicated in reducing bactericidal activity of aminoglycosides in sputum.
The time taken for resolution of adaptive resistance in vitro is dependent on the rate of elimination of antibiotic (Daikos et al., 1990; Barclay et al., 1992) . The half-life of elimination of aminoglycosides from the sputum after inhalation has not been reported previously, although the pharmacokinetics of aminoglycosides have been assessed in the serum after inhalation (Cooney et al., 1994) , and in the serum and sputum after intravenous administration (Hjelte, Malmborg & Strandvik, 1989) . The half-life of tobramycin in the sputum following administration by nebuliser in this study, at approximately 2 h, is similar to the serum half-life after intravenous administration (Horrevorts et al., 1988) .
The results of this study may have implications for aminoglycoside dosing regimens in CF. Once established, P. aeruginosa lung infection is difficult to eradicate, although current regimens of inhaled aminoglycoside are effective in reducing sputum bacterial counts (Ramsey et al., 1993) , improving pulmonary function (Hodson et al., 1981; Carswell et al., 1987; Stead, Hodson & Batten, 1987; Steinkamp et al., 1989; Ramsey et al., 1993) or slowing its rate of decline (Kun, Landau & Phelan, 1984; MacLusky et al., 1989) , and reducing the number of hospital admissions for exacerbations of lung infection (Hodson et al., 1981; Wall et al., 1983; Stead et al., 1987; Steinkamp et al., 1989) . Effectiveness of antimicrobial therapy may be due in part to an antibiotic-associated reduction in P. aeruginosa exoenzyme expression (Grimwood et al., \9%9a,b, 1993) , with delay of progressive lung injury. The place of adaptive resistance in this setting is not clear but it is probably important if eradication of P. aeruginosa from the sptuum is the primary aim of treatment.
Patients with CF are frequently treated with inhaled aminoglycoside administered two or three times per day. Our results suggest that it might be better to administer doses once every 24 or 48 h, when the adaptive resistance has had time to partly or completely abate. Much larger doses than used currently would provide a greater free drug concentration in the sputum for bactericidal activity, and toxicity should not be a problem because there is minimal systemic aminoglycoside absorption. There have been no trials in CF comparing different dose intervals for inhaled aminoglycoside therapy, and there are few trials comparing different intervals with intravenous aminogJycoside. Trials have compared once-daily aminoglycoside administration with continuous infusion (Powell et al., 1983) and thrice-daily administration (Heininger et al., 1993) and no difference between regimens was found in efficacy or toxicity. The difference in sputum aminoglycoside concentration achieved with intravenous or inhaled treatment is so great that the results from these studies may not be relevant to inhaled treatment.
In conclusion, adaptive resistance has been shown to occur in P. aeruginosa in humans following a dose of tobramycin, the time course characteristics of which are similar to those shown in vitro. This may have importance for developing optimal dose regimens of aminoglycosides in P. aeruginosa lung infection in CF and in the treatment of other P. aeruginosa infections. Benefits have been shown for the use of longer dosing intervals for aminoglycoside than used conventionally, and once-daily administration has been studied extensively in adults (Barclay, Begg & Hickling, 1994) . The results of this study add further support to the use of longer dose intervals, to allow time for adaptive resistance to abate, but suggest that the optimal interval may be longer than 24 h.
